21580 ⎘
Preparations containing radioactive substances for use in therapy or testing characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus; Organic compounds; Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
Sub-classes:Cysteine Engineered Antibodies and Conjugates
#2APPARATUS AND METHOD FOR MONITORING DISEASE
#3MODULAR SELF ASSEMBLY DISASSEMBLY (SADA) TECHNOLOGIES
#4Alpha Emitter Compositions And Methods
#5HUMANIZED ANTI-NUCLEAR ANTIBODIES FOR TARGETING NECROSIS IN CANCER THERAPY
#6ANTI-COMPLEMENT C1S ANTIBODIES AND USES THEREOF
#7Human Anti-SOD1 Antibodies
#8NUCLEIC ACID ORIGAMI PLATFORMS AND THEIR USES
#9NITROGEN-CONTAINING MACROCYCLIC CONJUGATES AS RADIOPHARMACEUTICALS
#10HIGH AFFINITY PD-1 AGENTS AND METHODS OF USE
#11THERAPEUTIC MOLECULES
#12Monoclonal Antibodies to Programmed Death 1 (PD-1)
#13METHOD FOR PRODUCING RADIOACTIVE METAL-LABELED ANTIBODY
#14MODULAR SELF ASSEMBLY DISASSEMBLY (SADA) TECHNOLOGIES
#15Methods of Noninvasive Detection and Specific Treatment for Cancer Metastasis
#16Cysteine Engineered Antibodies and Conjugates
#17COMPOSITION AND METHOD FOR MODIFYING POLYPEPTIDES
#18NANOPARTICLE IMMUNOCONJUGATES
#19Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy
#20ANTI-B7-H3 MONOCLONAL ANTIBODY AND METHODS OF USE THEREOF
#21REAGENTS AND METHODS FOR LABELING MOLECULES WITH ASTATINE ISOTOPES IN HIGHER OXIDATION STATES
#22Human Anti-SOD1 Antibodies
#23ANTI-CD137 ANTIBODIES AND METHODS OF USE THEREOF
#24Anti-complement C1s antibodies and uses thereof
#25Polynucleotides encoding monoclonal antibodies binding to human pituitary adenylate cyclase-activating polypeptide type I receptor (PAC1) and methods of making thereof
#26Human-derived anti-(poly-GA) dipeptide repeat (DPR) antibody
#27TRANSGLUTAMINASE CONJUGATION METHOD WITH A GLYCINE BASED LINKER
#28Therapeutic molecules
#29CONJUGATE COMPRISING LIGAND, SPACER, PEPTIDE LINKER, AND BIOMOLECULE
#30QUINUCLIDINE-3-ONE DERIVATIVES AND THEIR USE IN CANCER TREATMENT
#31Alpha emitter compositions and methods
#32CEACAM1 MEDIATED PROTECTIVE IMMUNITY
#33CEACAM1 BASED CANCER THERAPY AND DIAGNOSIS
#34System and Process for Production of Isotopes and Isotope Compositions
#35Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals
#36Antibody Molecules and Peptide Delivery Systems for Use in Alzheimer's Disease and Related Disorders
#37ASSAY FOR THE DIAGNOSIS OF MACULAR DEGENERATION
#38Spatial mapping of kidney functions
#39N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
#40Anti-CD137 antibodies and methods of use thereof
#41Cyclic compound/peptide comprising an A-beta13-16 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-beta13-16 peptide
#42Cyclic compound/peptide comprising an A-beta15-18 peptide and a linker that is covalently coupled to the n-terminus residue and the c-terminus residue of the A-BETA15-18 peptide
#43STABLE IgG4 ANTIBODIES
#44High affinity PD-1 agents and methods of use
#45Compositions comprising cyclic peptides derived from an A-beta peptide
#46Methods of using bispecific CD33 and CD3 binding proteins
#47Methods of Treating Antibody-Mediated Disorders with FcRn Antagonists
#48Methods for treating a headache condition using anti-human PAC1 antibodies or antigen-binding fragments thereof
#49Therapeutic molecules
#50NANOPARTICLE IMMUNOCONJUGATES
#51Nucleic acid encoding PCSK9 antibody
#52Metal complex forming compound, metal complex compound formed thereof, radioactive drug containing the metal complex compound, and method of using and preparing the metal complex compound
#53METHODS AND COMPOSITIONS FOR ENZYME-MEDIATED SITE-SPECIFIC RADIOLABELING OF GLYCOPROTEINS
#54Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
#55Humanized anti-nuclear antibodies for targeting necrosis in cancer therapy
#56Modular self assembly disassembly (SADA) technologies
#57Monoclonal Antibodies to Programmed Death 1 (PD-1)
#58Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals
#59Ultrasmall nanoparticles labeled with Zirconium-89 and methods thereof
#60ANTI-COMPLEMENT C1S ANTIBODIES AND USES THEREOF
#61Method for labeling radioisotope radiolabeling compound and kit comprising the same for labeling radioisotope
#62CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES
#63Modulation of immunity and CEACAM1 activity
#64Distribution of engineered-cysteine caps
#65Human anti-SOD1 antibodies
#66Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals
#67PAC1 antibodies and uses thereof
#68ANTI-ASCL1 ANTIBODIES AND METHODS OF USE
#69ANTIBODY DRUG CONJUGATES
#70Composition and method for modifying polypeptides
#71Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
#72Antibodies and related molecules and uses thereof
#73Targeting immunotherapy for amyloidosis
#74Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
#75Anti-PD-L1 nanobody and use thereof
#76Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
#77Anti-CD137 antibodies and methods of use thereof
#78Diagnostics and Therapeutics for Macular Degeneration-Related Disorders
#79N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto
#80Anti-amyloid beta antibodies binding to a cyclic amyloid beta peptide
#81TRANSGLUTAMINASE VARIANTS HAVING INCREASED SPECIFIC ACTIVITY
#82CEACAM1 BASED CANCER THERAPY AND DIAGNOSIS
#83CEACAM1 MEDIATED PROTECTIVE IMMUNITY
#84Selective reduction of the deleterious activity of extended tri-nucleotide repeat containing genes
#85Methods of using bispecific CD33 and CD3 binding proteins
#86ASSAY FOR THE DIAGNOSIS OF MACULAR DEGENERATION
#87Method for detecting AFP
#88METHODS AND COMPOSITIONS FOR ENZYME-MEDIATED SITE-SPECIFIC RADIOLABELING OF GLYCOPROTEINS
#89Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
#90PCSK9 antibody, and pharmaceutical composition and use thereof
#91Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
#92Podocalyxin and TRA-related antibody, methods of preparation and uses as an anti-cancer therapeutic agent
#93Targeting immunotherapy for amyloidosis
#94COMPOSITIONS AND METHODS TO SELECTIVELY BLOCK PAIN INDUCED BY COLD
#95High affinity PD-1 agents and methods of use
#96Anti-complement C1s antibodies
#97Monoclonal antibodies to programmed death 1 (PD-1)
#98Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof
#99Stable IgG4 antibodies
#100Monoclonal antibody and derivatives
#101Human anti-SOD1 antibodies
#102Selective reduction of the deleterious activity of extended tri-nucleotide repeat containing genes
#103Cysteine engineered antibodies and conjugates
#104Methods for identifying agents useful for modulating the expression and aggregation of CAG-expanded gene product in cells
#105Methods of inhibiting complement C4 activation with anti-complement C1s antibodies
#106TETRAZINES/TRANS-CYCLOOCTENES IN SOLID PHASE SYNTHESIS OF LABELED PEPTIDES
#107METHODS AND COMPOSITIONS FOR ENZYME-MEDIATED SITE-SPECIFIC RADIOLABELING OF GLYCOPROTEINS
#108Modulation of immunity and CEACAM1 activity
#109CEACAM1 mediated protective immunity
#110SELENOCYSTEINE MEDIATED HYBRID ANTIBODY MOLECULES
#111CX3CR1-targeting imaging agents and their use in the diagnosis and treatment of disease
#112Monoclonal antibodies to Programmed Death 1 (PD-1)
#113Methods for treating cancer using anti-PD-1 antibodies
#114Human anti-SOD1 antibodies
#115Monoclonal antibodies to programmed death 1 (PD-1)
#116Methods for treating cancer using anti-PD-1 antibodies in combination with anti-CTLA-4 antibodies
#117ARSENIC COMPLEXES FOR POTENTIAL DIAGNOSTIC APPLICATIONS
#118Methods for modulating the expression and aggregation of a CAG-expanded gene product in cells and methods for identifying agents useful for doing the same
#119Selective reduction of the deleterious activity of extended tri-nucleotide repeat containing genes
#120Methods and compositions for improved F-18 labeling of proteins, peptides and other molecules
#121ErbB interface peptidomimetics and methods of use thereof
#122Methods and compositions for protein labelling
#123Pretargeting kit, method and agents used therein
#124Compositions useful for target, detection, imaging and treatment, and methods of production and use thereof
#125DELIVERY OF AGENTS TO INFLAMED TISSUES USING FOLATE-TARGETED LIPOSOMES
#126Combinations and modes of administration of therapeutic agents and combination therapy
#127Immuno-conjugates and methods for producing them
#128Methods for modulating the expression and aggregation of CAG-expanded gene product in cells and methods for identifying agents useful for doing the same
#129Nitrogen-containing macrocyclic conjugates as radiopharmaceuticals
#130METHOD FOR INTRODUCING DOTA
#131Diagnostics and Therapeutics for Macular Degeneration-Related Disorders
#132Methods for radiolabeling macromolecules
#133HUMANIZED ANTI-ERBB2 ANTIBODIES AND TREATMENT WITH ANTI-ERBB2 ANTIBODIES
#134METHOD OF TREATING IMMUNE DISEASE USING B-CELL ANTIBODIES
#135Proteins with high immunoreactivity and method for their production
#136STABLE IGG4 ANTIBODIES
#137ErbB interface peptidomimetics and methods of use thereof
#138Methods and compositions for protein labelling
#139ErbB interface peptidomimetics and methods of use thereof
#140Selenocysteine mediated hybrid antibody molecules
#141ErbB interface peptidomimetics and methods of use thereof
#142Hexatriene-β-carbonyl compound
#143ErbB interface peptidomimetics and methods of use thereof
#144Mixtures Of Calcitonin Drug-Oligomer Conjugates And Methods Of Use In Pain Treatment
#145Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
#146Chimeric, human and humanized anti-granulocyte antibodies and methods of use
#147Combinations and modes of administration of therapeutic agents and combination therapy
#148Recombinant Peptides Derived from the Mc3 Anti-BA46 Antibody, Methods of Use Thereof, and Methods of Humanizing Antibody Peptides
#149Matriptase, a serine protease and its applications
#150CEACAM1 mediated protective immunity
#151Proteins with high immunoreactivity and method for their production
#152Methods and compositions for treating proliferative diseases
#153Compositions and uses thereof for identifying and targeting provasopressin-expressing cancer cells
#154Stabilized and Lyophilized Radiopharmaceutical Agents For Destroying Tumors
#155Polymeric chelators for radionuclide delivery systems
#156Mixtures Of Calcitonin Drug-Oligomer Conjugates And Methods Of Use In Pain Treatment
#157Chimeric, human and humanized anti-granulocyte antibodies and methods of use
#158STABILIZED AND LYOPHILIZED RADIOPHARMACEUTICAL AGENTS FOR DESTROYING TUMORS
#159Methods and compositions for treating proliferative diseases
#160Modulation of immunity and CEACAM1 activity
#161STABILIZED AND LYOPHILIZED RADIOPHARMACEUTICAL AGENTS
#162Inhibition of inward sodium currents in cancer
#163CEACAM1 based cancer therapy and diagnosis
#164Polypeptide and protein derivatives and process for their preparation
#165Diagnostics and therapeutics for macular degeneration-related disorders
#166Combinations and modes of administration of therapeutic agents and combination therapy
#167Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
#168Treatment with anti-ErbB2 antibodies and chemotherapeutic agents
#169Humanized anti-ERBB2 antibodies and treatment with anti-ERBB2 antibodies
#170Modulation of sodium channels in dorsal root ganglia
#171Novel epithelial tissue imaging agent
#172Treatment with anti-ErbB2 antibodies and anti-hormonal compounds
#173Method of affecting a function of or ablating a non-malignant cell
#174Treatment with anti-ErbB2 antibody combinations
#175Targeted combination immunotherapy of cancer and infectious diseases
#176Stablilized and lyophilized radiopharmaceutical agents
#177Novel method of diagnosing, monitoring, staging, imaging and treating colon cancer
#178Treatment with anti-ErbB2 antibodies and EGFR-targeted drugs
#179Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
#180Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
#181Novel method of diagnosing, monitoring, staging, imaging and treating cancer
#182Labeled ligands for lectin-like oxidized low-density lipoprotein receptor (LOX-1)
#183System and process for production of isotopes and isotope compositions